Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:14999611rdf:typepubmed:Citationlld:pubmed
pubmed-article:14999611lifeskim:mentionsumls-concept:C0019682lld:lifeskim
pubmed-article:14999611lifeskim:mentionsumls-concept:C0019699lld:lifeskim
pubmed-article:14999611lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:14999611lifeskim:mentionsumls-concept:C0036043lld:lifeskim
pubmed-article:14999611lifeskim:mentionsumls-concept:C0332466lld:lifeskim
pubmed-article:14999611lifeskim:mentionsumls-concept:C1999216lld:lifeskim
pubmed-article:14999611pubmed:issue6lld:pubmed
pubmed-article:14999611pubmed:dateCreated2004-3-4lld:pubmed
pubmed-article:14999611pubmed:abstractTextT-1249 is a 39-aa synthetic peptide that inhibits fusion of human immunodeficiency virus (HIV) to the host target cell. A 14-day open-label, phase 1/2 dose-escalation monotherapy study of the safety and antiretroviral activity of T-1249 was performed on 115 HIV-1-infected adults. At baseline, the majority of the patients had advanced HIV disease (baseline median CD4(+) cell count, 57 cells/microL) and had extensive pretreatment (i.e., pre-T-1249) experience with antiretroviral medications (median, 11 antiretroviral drugs). Patients received T-1249 monotherapy by subcutaneous injection, for 14 days, at doses ranging from 6.25 to 192 mg/day. T-1249 was generally well tolerated, and no dose-limiting toxicity was identified. Injection-site reactions were the most commonly reported adverse event (57%). Dose-dependent decreases in plasma HIV-1 RNA load were observed; the median maximum change from baseline across dose groups ranged from -0.29 log(10) copies/mL (95% confidence interval [CI], -0.43 to -0.05 log(10) copies/mL) for the lowest dose to -1.96 log(10) copies/mL (95% CI, -2.02 to -1.37 copies/mL) for the highest dose. These results indicate that T-1249 is a potent new therapeutic agent for HIV-1 infection.lld:pubmed
pubmed-article:14999611pubmed:languageenglld:pubmed
pubmed-article:14999611pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14999611pubmed:citationSubsetAIMlld:pubmed
pubmed-article:14999611pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14999611pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14999611pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14999611pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14999611pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14999611pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14999611pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14999611pubmed:statusMEDLINElld:pubmed
pubmed-article:14999611pubmed:monthMarlld:pubmed
pubmed-article:14999611pubmed:issn0022-1899lld:pubmed
pubmed-article:14999611pubmed:authorpubmed-author:GreenbergMich...lld:pubmed
pubmed-article:14999611pubmed:authorpubmed-author:BartlettJohn...lld:pubmed
pubmed-article:14999611pubmed:authorpubmed-author:KilbyJ...lld:pubmed
pubmed-article:14999611pubmed:authorpubmed-author:ZhangYingYlld:pubmed
pubmed-article:14999611pubmed:authorpubmed-author:GulickRoy MRMlld:pubmed
pubmed-article:14999611pubmed:authorpubmed-author:EronJoseph...lld:pubmed
pubmed-article:14999611pubmed:authorpubmed-author:MirallesG...lld:pubmed
pubmed-article:14999611pubmed:authorpubmed-author:MeriganThomas...lld:pubmed
pubmed-article:14999611pubmed:authorpubmed-author:DeMasiRalphRlld:pubmed
pubmed-article:14999611pubmed:authorpubmed-author:DrobnesClaude...lld:pubmed
pubmed-article:14999611pubmed:authorpubmed-author:RaskinoClaire...lld:pubmed
pubmed-article:14999611pubmed:authorpubmed-author:ArduinoRobert...lld:pubmed
pubmed-article:14999611pubmed:authorpubmed-author:YangcoBienven...lld:pubmed
pubmed-article:14999611pubmed:authorpubmed-author:DiersAdriannAlld:pubmed
pubmed-article:14999611pubmed:authorpubmed-author:MelbyThomasTlld:pubmed
pubmed-article:14999611pubmed:authorpubmed-author:RusnakPamPlld:pubmed
pubmed-article:14999611pubmed:authorpubmed-author:SpenceRebecca...lld:pubmed
pubmed-article:14999611pubmed:issnTypePrintlld:pubmed
pubmed-article:14999611pubmed:day15lld:pubmed
pubmed-article:14999611pubmed:volume189lld:pubmed
pubmed-article:14999611pubmed:ownerNLMlld:pubmed
pubmed-article:14999611pubmed:authorsCompleteYlld:pubmed
pubmed-article:14999611pubmed:pagination1075-83lld:pubmed
pubmed-article:14999611pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:14999611pubmed:meshHeadingpubmed-meshheading:14999611...lld:pubmed
pubmed-article:14999611pubmed:meshHeadingpubmed-meshheading:14999611...lld:pubmed
pubmed-article:14999611pubmed:meshHeadingpubmed-meshheading:14999611...lld:pubmed
pubmed-article:14999611pubmed:meshHeadingpubmed-meshheading:14999611...lld:pubmed
pubmed-article:14999611pubmed:meshHeadingpubmed-meshheading:14999611...lld:pubmed
pubmed-article:14999611pubmed:meshHeadingpubmed-meshheading:14999611...lld:pubmed
pubmed-article:14999611pubmed:meshHeadingpubmed-meshheading:14999611...lld:pubmed
pubmed-article:14999611pubmed:meshHeadingpubmed-meshheading:14999611...lld:pubmed
pubmed-article:14999611pubmed:meshHeadingpubmed-meshheading:14999611...lld:pubmed
pubmed-article:14999611pubmed:meshHeadingpubmed-meshheading:14999611...lld:pubmed
pubmed-article:14999611pubmed:meshHeadingpubmed-meshheading:14999611...lld:pubmed
pubmed-article:14999611pubmed:meshHeadingpubmed-meshheading:14999611...lld:pubmed
pubmed-article:14999611pubmed:meshHeadingpubmed-meshheading:14999611...lld:pubmed
pubmed-article:14999611pubmed:meshHeadingpubmed-meshheading:14999611...lld:pubmed
pubmed-article:14999611pubmed:meshHeadingpubmed-meshheading:14999611...lld:pubmed
pubmed-article:14999611pubmed:year2004lld:pubmed
pubmed-article:14999611pubmed:articleTitleShort-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV.lld:pubmed
pubmed-article:14999611pubmed:affiliationDivision of Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.lld:pubmed
pubmed-article:14999611pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:14999611pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:14999611pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:14999611pubmed:publicationTypeMulticenter Studylld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14999611lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14999611lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14999611lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14999611lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14999611lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14999611lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14999611lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14999611lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14999611lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14999611lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14999611lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14999611lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14999611lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14999611lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14999611lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14999611lld:pubmed